Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxic...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Sriskandarajah, Priya, De Haven Brandon, Alexis, MacLeod, Kenneth, Carragher, Neil O., Kirkin, Vladimir, Kaiser, Martin, Whittaker, Steven R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106683/
https://ncbi.nlm.nih.gov/pubmed/32228485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06735-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg